{"id":"https://openalex.org/W1997018189","doi":"https://doi.org/10.1111/j.1463-1326.2011.01406.x","title":"Canagliflozin, a novel inhibitor of sodium glucose co\u2010transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","display_name":"Canagliflozin, a novel inhibitor of sodium glucose co\u2010transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","publication_year":2011,"publication_date":"2011-04-01","ids":{"openalex":"https://openalex.org/W1997018189","doi":"https://doi.org/10.1111/j.1463-1326.2011.01406.x","mag":"1997018189","pmid":"https://pubmed.ncbi.nlm.nih.gov/21457428"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2011.01406.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01406.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01406.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1997018189"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113701102","display_name":"Sue Sha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"S. Sha","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ 08869, USA. ssha@its.jnj.com","Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ 08869, USA. ssha@its.jnj.com","institution_ids":["https://openalex.org/I4405282460"]},{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047898874","display_name":"Damayanthi Devineni","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Devineni","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107929496","display_name":"A. Ghosh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Ghosh","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022867432","display_name":"David Polidori","orcid":"https://orcid.org/0000-0002-8427-5663","observed_orcids":["https://orcid.org/0000-0002-8427-5663"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Polidori","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, La Jolla, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108522995","display_name":"Shuchean Chien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Chien","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060475451","display_name":"David B. Wexler","orcid":"https://orcid.org/0000-0003-4121-8973","observed_orcids":["https://orcid.org/0000-0003-4121-8973"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Wexler","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, La Jolla, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052959100","display_name":"Kevin Shalayda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Shalayda","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089781644","display_name":"Keith T. Demarest","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Demarest","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081074918","display_name":"Paul Rothenberg","orcid":"https://orcid.org/0000-0001-9570-6927","observed_orcids":["https://orcid.org/0000-0001-9570-6927"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Rothenberg","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA","institution_ids":["https://openalex.org/I4405282460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5113701102"],"corresponding_institution_ids":["https://openalex.org/I4405282460"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":19.5216,"has_fulltext":false,"cited_by_count":300,"citation_normalized_percentile":{"value":0.99700684,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"13","issue":"7","first_page":"669","last_page":"672"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/canagliflozin","display_name":"canagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9129999876022339},{"id":"https://openalex.org/keywords/urinary-glucose-excretion","display_name":"urinary glucose excretion","score":0.9869999885559082},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.7649999856948853},{"id":"https://openalex.org/keywords/serum-insulin","display_name":"serum insulin","score":0.8519999980926514},{"id":"https://openalex.org/keywords/type-2-diabetes-treatment","display_name":"type 2 diabetes treatment","score":0.7689999938011169},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.7960000038146973},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.7319999933242798}],"concepts":[{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.9923276901245117},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6339778900146484},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.619005560874939},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5938223004341125},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5773904323577881},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.5452597141265869},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5388085842132568},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.5098046660423279},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.491506427526474},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4640888571739197},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4095069468021393},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3434597849845886},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2818540334701538},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068896","descriptor_name":"Canagliflozin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006029","descriptor_name":"Glycosuria","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006029","descriptor_name":"Glycosuria","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2011.01406.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01406.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01406.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:21457428","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21457428","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":8,"referenced_works":["https://openalex.org/W2013962406","https://openalex.org/W2043121816","https://openalex.org/W2050614267","https://openalex.org/W2059373374","https://openalex.org/W2090088543","https://openalex.org/W2149973065","https://openalex.org/W2152397610","https://openalex.org/W2585015296"],"related_works":["https://openalex.org/W2080051183","https://openalex.org/W2013892321","https://openalex.org/W1867144247","https://openalex.org/W2021988691","https://openalex.org/W2052526874","https://openalex.org/W2373302420","https://openalex.org/W1606165384","https://openalex.org/W2036140026","https://openalex.org/W576542637","https://openalex.org/W1835375518"],"abstract_inverted_index":{"Canagliflozin,":[0],"a":[1],"potent,":[2],"selective":[3],"sodium":[4],"glucose":[5,19,27,33],"co-transporter":[6],"2":[7,15],"inhibitor":[8],"in":[9,50],"development":[10],"for":[11,26],"treatment":[12],"of":[13,48,152],"type":[14],"diabetes,":[16],"lowers":[17],"plasma":[18],"(PG)":[20],"by":[21],"lowering":[22],"the":[23],"renal":[24],"threshold":[25],"(RT(G)":[28],")":[29],"and":[30,46,109,125,142],"increasing":[31],"urinary":[32],"excretion":[34],"(UGE).":[35],"An":[36],"ascending":[37],"single":[38],"oral-dose":[39],"phase":[40],"1":[41],"study":[42,151],"investigated":[43],"safety,":[44],"tolerability":[45],"pharmacodynamics":[47],"canagliflozin":[49,59,96,121],"healthy":[51],"men":[52],"(N":[53],"=":[54,61,66],"63)":[55],"randomized":[56],"to":[57,85,105],"receive":[58],"(n":[60,65],"48)":[62],"or":[63,75,79],"placebo":[64],"15).":[67],"Canagliflozin":[68,132],"(10,":[69],"30,":[70],"100,":[71],"200,":[72],"400,":[73],"600":[74],"800":[76],"mg":[77,81,117],"q.d.":[78],"400":[80],"b.i.d.)":[82],"was":[83,133,145],"administered":[84,118],"eight":[86],"cohorts":[87],"(six":[88],"subjects/cohort:":[89,92],"canagliflozin;":[90],"two":[91],"placebo).":[93],"Dose":[94],"dependently,":[95],"decreased":[97],"calculated":[98],"24-h":[99,112],"mean":[100,111],"RT(G)":[101],"with":[102],"maximal":[103],"reduction":[104],"approximately":[106],"60":[107],"mg/dl,":[108],"increased":[110],"UGE.":[113],"At":[114],"doses":[115],">200":[116],"before":[119],"breakfast,":[120],"reduced":[122],"postprandial":[123],"PG":[124],"serum":[126],"insulin":[127],"excursions":[128],"at":[129],"that":[130],"meal.":[131],"generally":[134],"well":[135],"tolerated;":[136],"most":[137],"adverse":[138],"events":[139],"were":[140],"mild":[141],"no":[143],"hypoglycaemia":[144],"reported.":[146],"These":[147],"results":[148],"support":[149],"further":[150],"canagliflozin.":[153]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":24},{"year":2017,"cited_by_count":29},{"year":2016,"cited_by_count":30},{"year":2015,"cited_by_count":42},{"year":2014,"cited_by_count":44},{"year":2013,"cited_by_count":37},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}